2020 has been a challenging year, the outbreak of COVID-19 has brought upon unprecedented challenges, have made a significant impact on global economic development and cooperation as well. However, as an international innovation platform, iCCAMT has always focused on life science and healthcare innovation, bridging domestic innovative resources to the world, and introducing overseas companies to China. 

On December 4th, the 3rd Sino-EU Innovation Conference of Health Technology successfully concluded in Nanjing Xuzhuang High-tech Zone! The conference was organized by iCCAMT, supported by Biocat, Medical Valley, Technopark Allienz and Steinbeis.

This event aims to bridge Europe and China's technology entrepreneurs and investors together, integrate resources to benefit China's innovation ecosystems and market. Mr. Shen Jianrong, Deputy Mayor of Nanjing, Mr. Bernhard Weber, Chelf Representative of the State Baden-Württemberg in China and Dr.-Ing. Tobias Arndt, General Manager of Global Advanced Manufacturing Institute (GAMI), as well as more than 100+ authoritative experts, entrepreneur attending this overseas collaborative innovation conference.

During this event, Dr hui WU, CEO of iCCAMT has signed a strategy cooperation MOU with Mr. Jordi Naval, CEO of Biocat online. Both would develop and implement joint collaboration in biotechnology and healthcare fields between China and Catalonia, Spain.

Meanwhile, the LifeCube public experimental platform, a core facility operated by iCCAMT and Nanjing Xuzhuang government, was officially launched.  LifeCube platform is consisting of the Cell factory, IVD & Omics Space, and Molecular Bench. The laboratory is equipped with advanced equipment for cell therapy and precision medicine such as flow cytometry, qPCR, bioanalyzer. It aims to helps the startups in our incubation focus on R&D works at a lower cost, and accelerate their development to the next stage. 

3 innovation projects from Catalonia have presented online: Bioengineering solutions for healthcare project working on organoids for COVID drug testing; Able human motion, a Barcelona-based company developing robotic exoskeletons to improve the quality of life of people with disabilities; MJN Neuro, an innovation company aims to improve the quality of life of epilepsy-affected people, with the first wearable device, MJN-SERAS, that can alert patients before seizures occur by the continuous monitoring of brain signals.